Wanda Boote, MD
Dermatology · St Petersburg, FLNPI 1063517050
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,292 of the $1,901 with a category attached, or 68.0%. Pfizer accounts for 90.5% of it on its own, with 5 other manufacturers making up the rest. 2023 is the largest year on record at $1,758, more than ten times the $119 reported in 2019. That places this record below the midpoint for dermatology clinicians in FL, where the typical reported total is $2,563.
Across 15 payments — averaging $126.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$2K
- DUSA Pharmaceuticals, Inc.$70
- Dermavant Sciences, Inc.$37
- Merz North America, Inc.$25
- Sun Pharmaceutical Industries Inc.$24
- Smith+Nephew$24
Across 144 payments — averaging $7458.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$494K
- Bristol Myers Squibb$198K
- Genentech, Inc.$111K
- Janssen Research & Development, LLC$102K
- E.r. Squibb & Sons, L.L.C.$75K
- Eli Lilly$52K
- plus $43K from 2 others
What the payments were for
- Travel & lodging$1,29268%
- Food & beverage$60832%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 6 | $1,721 |
| DUSA Pharmaceuticals, Inc. | 4 | $70 |
| Dermavant Sciences, Inc. | 2 | $37 |
| Merz North America, Inc. | 1 | $25 |
| Sun Pharmaceutical Industries Inc. | 1 | $24 |
| Smith+Nephew | 1 | $24 |
How this compares
$1,901 in reported general payments places this provider in the 40th percentile of 1,147 dermatology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Metronidazole | 14 | $1,367 |
| Diclofenac Sodium | 15 | $725 |
| Ketoconazole | 57 | $720 |
| Ammonium Lactate | 28 | $646 |
| Mupirocin | 51 | $397 |
| Mometasone Furoate | 15 | $235 |
| Triamcinolone Acetonide | 35 | $234 |
Paid to pharmacies, not to this prescriber.
Other dermatology in St Petersburg
- Francisco KerdelMiami$2.1M
- Brad GlickMargate$2M
- Robert KirsnerMiami$1.4M
- John MinniStuart$1.4M
- Gil YosipovitchMiami$1M
- Shino Bay AguileraFt Lauderdale$1M
- Robert SnyderPembroke Pines$1M
- Marc IngleseTallahassee$989K
- Jeremy GreenCoral Gables$952K
- Mercedes GonzalezMiami$943K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.